CURASIGHT A/S |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.3 DKK | -4.71% |
|
-11.00% | -47.61% |
| Apr. 16 | Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients | CI |
| Apr. 12 | Curasight A/S Announces Board Changes | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 353M 2.42B |
|---|---|---|---|---|---|
| Net income 2022 | -18M -124M | Net income 2023 | -26M -178M | EV / Sales 2022 | - |
| Net cash position 2022 | 49.94M 343M | Net cash position 2023 | 20.08M 138M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-11.1
x | P/E ratio 2023 |
-13.4
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.23% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.71% | ||
| 1 week | -11.00% | ||
| Current month | -8.82% | ||
| 1 month | -7.46% | ||
| 3 months | -43.98% | ||
| 6 months | -51.31% | ||
| Current year | -47.61% |
1 week
9.30
9.98
1 month
9.0010.55
Current year
8.1619.90
1 year
8.1629.00
3 years
8.1633.60
5 years
8.1644.05
10 years
8.1644.05
| Managers | Title | Age | Since |
|---|---|---|---|
Carsten Nielsen
FOU | Founder | 41 | 12-12-31 |
Jacob Madsen
FOU | Founder | 52 | 12-12-31 |
Andreas Kjaer
FOU | Founder | 61 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kirsten Drejer
BRD | Director/Board Member | 68 | 21-05-03 |
Per Falholt
CHM | Chairman | 65 | 19-12-31 |
| Chief Executive Officer | 57 | 15-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 9.3 | -4.71% | 5,075 |
| 24-05-16 | 9.76 | -1.41% | 2,509 |
| 24-05-15 | 9.9 | -0.80% | 3,679 |
| 24-05-14 | 9.98 | -4.50% | 6,785 |
End-of-day quote NORDIC GROWTH MARKET, May 16, 2024
More quotes
Curasight A/S is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (uPAR). The technology provides improved diagnosis and risk stratification in multiple cancer types.
Calendar
2024-05-22
- Q1 2024 Earnings Release
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -47.61% | 26.94M | |
| +41.79% | 54.04B | |
| -0.56% | 41.92B | |
| +47.70% | 41.96B | |
| -7.20% | 28.35B | |
| +12.59% | 26.35B | |
| -21.51% | 19B | |
| +6.92% | 13B | |
| +24.91% | 12.19B | |
| +29.60% | 12.28B |
- Stock Market
- Equities
- CURAS Stock
